logo

Scynexis, Inc. (SCYX)



Trade SCYX now with
  Date
  Headline
9/22/2021 8:55:25 AM SCYNEXIS Reports US Availability Of BREXAFEMME,Antifungal Class Of Therapy Approved By FDA For Vaginal Yeast Infections
11/6/2020 8:53:34 AM SCYNEXIS Q3 Loss/Shr $0.28 Vs Loss $1.45 Last Year
8/10/2020 8:23:06 AM SCYNEXIS Q2 Net Loss $6.4 Mln Or $0.64/shr Vs Loss Of $8.4 Mln Or $1.58/shr Last Year
2/13/2020 8:09:49 AM SCYNEXIS Completes Patient Enrollment Ahead Of Schedule In 2nd Pivotal Phase 3 Study (VANISH-306) Of Oral Ibrexafungerp
1/8/2020 7:35:50 AM SCYNEXIS Announces Positive Results From The Second Interim Analysis Of Ongoing Phase 3 FURI Study
10/7/2016 7:26:48 AM WBB Securities Lifts SCYNEXIS, Inc. (SCYX) To Strong Buy From Buy With $8 Price Target
11/16/2015 8:50:03 AM RBC Capital Markets Is Lowering SCYNEXIS, Inc. (SCYX) FY17 Estimate To -2.63 From -2.15
11/16/2015 8:49:45 AM RBC Capital Markets Is Cutting SCYNEXIS, Inc. (SCYX) FY16 Estimate To -2.19 From -1.63
11/16/2015 8:49:01 AM RBC Capital Markets Is Lowering SCYNEXIS, Inc. (SCYX) FY15 Estimate To -2.36 From -2.32
11/16/2015 8:48:31 AM RBC Capital Markets Is Cutting SCYNEXIS, Inc. (SCYX) Q4 15 Estimate To -0.60 From -0.57
5/29/2014 10:05:30 AM RBC Capital Markets Starts SCYNEXIS, Inc. (SCYX) At Outperform With $17 Price Target